Stock info Kiadis | Filter  Basic-Info

Kiadis

The past year was a relatively good year for Kiadis investors

The stock lost over the past 12 months at around 27 percent. Kiadis' stock lost the past 5 years at around 0 percent.

Over the past 10 years the global pharmaceutical companies gained around 75 percent. As from 2011 the sector is 147 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 75 percent.

The Belgian company didn't pay out any dividends (in the past 5 years).

Kiadis financed with a quite low debt position

At the end of 2015 the pharmaceutical company's balance sheet was worth 42,27 million euros. Last year the total debt of the company was 16,62 million euros. This equals around 39,32 percent of the total balance sheet. The Belgian company's price/earnings-ratio was -9. So the market valued the stock at -9 times the 2015' earnings per share. Based on it's price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.

The pharmaceutical company's market capitalization (the number of shares outstanding times the market value) equaled around 147,82 million euros. At the end of 2015 the Belgian company had around 12,06 million stocks listed on the exchanges.

At this page you find all Kiadis's financial reports. More information about Kiadis can be found it's website. .